Soluble levels of 4‐1BB (CD137) and OX40 (CD134) are associated with cancer progression in gastric adenocarcinoma

Abstract

AbstractBackground and ObjectivesPrevious studies have demonstrated that soluble forms of T‐cell costimulatory molecules 4‐1BB (s4‐1BB) and OX40 (sOX40) interact with immune cells and may constitute a mechanism of immune evasion by tumors in various cancers. The role of the soluble forms of 4‐1BB and OX40 in GC remains unclear. We aimed to examine the association between serum levels of s4‐1BB and sOX40 and tumor progression in patients with GC.MethodsBetween 2017 and 2018, a cross‐sectional study was performed with serum samples of 83 GC patients and 20 healthy controls.ResultsPatients with stage IV metastatic gastric cancer had significantly higher levels of soluble OX40 in comparison with stage III patients with lymph nodes metastasis (p = 0.0003) and stages I and II patients (p = 0.005), whereas the opposite was found for soluble 4‐1BB levels, with lower levels being found in advanced stage III (p = 0.003) compared with initial stages I/II.ConclusionsThe sOX40 and s4‐1BB‐mediated T cell interactions may be involved in antitumor immune responses in GC, possibly favoring tumor escape and progression. Serum levels of sOX40 and s4‐1BB are associated with staging in GC and may constitute biomarkers for prognosis, as well as potential targets for immunotherapy.